Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 4, 2015

FDA approves Dako’s new diagnostic assay for lung cancer

The US Food and Drug Administration (FDA) has granted approval for Agilent Technologies company Dako's new companion diagnostic assay PD-L1 IHC 22C3 pharmDx.

The US Food and Drug Administration (FDA) has granted approval for Agilent Technologies company Dako’s new companion diagnostic assay PD-L1 IHC 22C3 pharmDx.

The assay can reveal whether a patient with advanced non-small cell lung cancer (NSCLC) is likely to respond to a new form of treatment.

The approval of the assay strengthens the company’s portfolio of companion diagnostics and its position in developing and commercialising companion diagnostic products.

PD-L1 IHC 22C3 pharmDx was developed by Dako in collaboration with Merck, which makes anti-PD-1 therapy Keytruda (pembrolizumab).

The FDA approved Keytruda to treat patients with metastatic NSCLC whose tumours express PD-L1 as determined by the companion diagnostic assay and have disease progression on or after platinum containing chemotherapy.

Keytruda is an immunotherapy that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, helping the immune system to help detect and fight cancer cells.

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

The drug can also cause the immune system to attack normal organs and tissues.

"The approval of the first PD-L1 diagnostic has the potential to provide information that will help guide treatment decisions for many patients."

Agilent Diagnostics and Genomics Group president Jacob Thaysen said: "Because individuals often respond differently to the same treatment, scientists have been putting more emphasis on personalised medicine, which is where PD-L1 IHC 22C3 pharmDx comes into play.

"This is a new era in immunoncology, and we are particularly excited about Agilent’s involvement in advancements in cancer treatment and the potential PD-L1 IHC 22C3 pharmDx has in helping to identify patients with non-small cell lung cancer who are most likely to benefit from treatment with Keytruda."

With the assay approved in the US, the company intends to secure regulatory approval for the new diagnostic in Canada, Europe and other jurisdictions next year.

The company noted PD-L1 IHC 22C3 pharmDx is the first and only companion diagnostic assay that has been validated and approved to identify NSCLC patients eligible for Keytruda.

Merck Research Laboratories senior vice-president Dr Roger Dansey said: "The approval of the first PD-L1 diagnostic has the potential to provide information that will help guide treatment decisions for many patients.

"PD-L1 is an important new biomarker, and we look forward to working with Dako to make PD-L1 testing a routine part of the diagnosis and treatment of non-small cell lung cancer."

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU